Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 20, 2026

Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?

View original at finance.yahoo.com
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? Merck & Co. MRK and Bristol Myers Squibb BMY are major global drugmakers with expansive, diversified portfolios…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Zacks Consensus Estimate for BMY's 2026 sales implies year-over-year decrease of 2.32%

    80% confidence

  • Phase III pipeline has almost tripled since 2021

    80% confidence

  • BMY's relatively attractive valuation and more favorable 2026 outlook position it as the more compelling investment choice versus MRK at present

    80% confidence

  • Expects headwind of approximately $2.5 billion from generic competition in 2026

    80% confidence

  • Zacks Consensus Estimate for MRK's 2026 sales implies year-over-year increase of 2.59%

    80% confidence

  • Keytruda targets peak sales of $35 billion by 2028

    80% confidence

  • Annual revenue guidance of $46.0-$47.5 billion for 2026

    80% confidence

  • Zacks Consensus Estimate for MRK's 2026 EPS suggests decline of 38.75%

    80% confidence

  • Expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s

    80% confidence

  • Positioned to launch around 20 drugs over the next few years, with many having blockbuster potential

    80% confidence

  • Zacks Consensus Estimate for BMY's 2026 EPS suggests increase of 0.33%

    80% confidence

  • Keytruda will lose patient exclusivity in 2028

    80% confidence

  • Legacy Portfolio sales expected to decline 12-16% in 2026

    80% confidence

  • Targeting $2 billion in annualized cost savings by the end of 2027

    80% confidence

  • Achieved approximately $1 billion in savings in 2025

    80% confidence

  • Operating expenses expected to decline in 2026, supporting margin expansion

    80% confidence